Summary
This Nature Reviews Genetics article surveys contemporary understanding of the genetic architecture of amyotrophic lateral sclerosis and assesses the translational pathway from genomic discovery to clinical therapy. The authors synthesise recent progress in identifying disease-causing and disease-modifying genetic variants, and discuss how these insights are informing drug development and patient stratification strategies. As suggested by the title and journal scope, the paper addresses the challenge of converting genetic knowledge into effective treatments for this rapidly advancing field.
Regional applicability
The genetic findings and therapeutic approaches reviewed are internationally applicable, including to UK clinical practice and NHS treatment pathways. UK-based clinical genetics services and neurology departments may use these findings to inform patient counselling, genetic testing strategies, and access to emerging therapies.
Key measures
Genetic variants associated with ALS; therapeutic targets derived from genetic findings; clinical trial outcomes for genetically-informed treatments
Outcomes reported
The paper reviews recent genetic discoveries in amyotrophic lateral sclerosis (ALS) and examines how these findings are being translated into therapeutic approaches. It synthesises evidence on genetic risk factors and their potential clinical applications.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.